Granules India Ltd received ANDA Approval for Losartan Potassium Tablets

Granules India Limited announced today that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg.

It is bioequivalent to the reference listed drug product (RLD), Cozaar Tablets of Organon LLC. Granules now has a total of 54 ANDA approvals from US FDA (52 Final approvals and 2 tentative approvals).

Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.

The current annual U.S. market for Losartan potassium Tablets is approximately $336 Million, according to MAT Dec 2022, IQVIA/IMS Health.

Granules India Limited has consistently achieved manufacturing success, set new standards of quality, and expanded its presence across the world.

Shares of Granules India Limited was last trading in BSE at Rs. 285.30 as compared to the previous close of Rs. 283.40. The total number of shares traded during the day was 37868 in over 1485 trades.

The stock hit an intraday high of Rs. 287.55 and intraday low of 281.90. The net turnover during the day was Rs. 10776974.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 Pharmaceuticals USFDA ANDAApproval LosartanPotassiumTablets